Fulgent Genetics (FLGT) Short-term Investments (2016 - 2026)

Fulgent Genetics has reported Short-term Investments for 11 years, with the latest figure at $230.7 million in Q2 2026.

• Quarterly Short-term Investments rose 12.52% year-over-year to $230.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $230.7 million (up 12.52% YoY) and the FY2025 annual result came in at $285.9 million, up 40.86% from the prior year.
• Short-term Investments eased to $230.7 million in Q2 2026 per FLGT's latest filing, from $252.9 million in the prior quarter.
• Over five years, Short-term Investments peaked at $446.7 million in Q4 2022 and troughed at $155.0 million in Q3 2024.
• A 5-year average of $297.1 million and a median of $255.6 million in 2025 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments soared 88.89% in 2023, then slumped 59.6% in 2024.
• Over 5 years, Short-term Investments stood at $446.7 million in 2022, then dropped by 26.87% to $326.7 million in 2023, then sank by 37.87% to $203.0 million in 2024, then soared by 40.86% to $285.9 million in 2025, then dropped by 19.29% to $230.7 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $230.7 million, $252.9 million, and $285.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.